查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612605

出血性疾病诊断市场：按诊断测试、适应症和最终用途分类 - 全球预测 2025-2030

Bleeding Disorder Diagnostics Market by Diagnostic Tests (Bleeding Time, Genetic Tests, Platelet Aggregation Tests), Indication (Hemophilia A & Hemophilia B, Platelet Function Disorders, Von Willebrand Disease), End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，出血性疾病诊断市场价值为66287万美元，预计2024年将达到71026万美元，复合年增长率为7.60%，到2030年将达到110709万美元。

出血性疾病诊断市场包括用于检测和诊断血友病、冯维勒布兰德病和血小板功能障碍等出血性疾病的各种检查和工具。早期发现、有效管理和预防这些疾病併发症的需要推动了对准确诊断的需求。其应用主要集中在医院和专业诊断中心的实验室血液凝固检验、基因测试和出血评估。受益于这些诊断的最终用户包括满足患者更好治疗结果需求的医疗保健提供者以及专注于药物开发和临床测试的製药公司。

主要市场统计
基准年[2023] 66287万美元
预测年份 [2024] 71026万美元
预测年份 [2030] 1,107.09百万美元
复合年增长率（%） 7.60%

关键的成长要素包括遗传性疾病数量的增加、对出血性疾病的认识提高以及诊断技术的进步，例如就地检验和自动化。新兴国家医疗基础设施的扩张带来了利润丰厚的机会，基因组和蛋白质组学方法的完善也提高了诊断的准确性。公司可以透过专注于个人化医疗和开发具有成本效益的快速诊断解决方案来开拓市场。挑战包括高级测试成本高昂、某些地区的认知度较低以及监管审批的严格性。

分子诊断和生物资讯学的创新代表了研究和业务扩展的有前途的途径。重要的是要注重研究和开发，开发新的生物标记物，以便早期、准确地识别出血性疾病。此外，促进与研究机构的合作以及投资人工智慧主导的诊断工具可以推动成长。该市场表现出竞争性，老牌医疗巨头和专注于利基市场的新兴参与企业都对此表现出浓厚的兴趣。然而，克服监管环境并确保广泛的可及性仍然是持续存在的挑战。公司应优先考虑负担得起的测试解决方案和策略伙伴关係，以提高市场渗透率并保持竞争优势。

市场动态：揭示快速发展的出血性疾病诊断市场的关键市场洞察

供需的动态交互作用正在改变出血性疾病诊断市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 出血性疾病盛行率增加
    • 提高一般民众和卫生专业人员对出血性疾病的认识和承诺
  • 市场限制因素
    • 与先进的出血性疾病诊断方法相关的高成本
  • 市场机会
    • 尖端技术在出血性疾病诊断药物中的新可能性
    • 扩大照护现场出血性疾病检测设备的采用
  • 市场问题
    • 区域医疗保健监管的监管复杂性和动态性

波特五力：驾驭出血性疾病诊断市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解出血性疾病诊断市场的外部影响

外部宏观环境因素在塑造出血性疾病诊断市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解出血性疾病诊断市场的竞争格局

对出血性疾病诊断市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：出血性疾病诊断市场供应商的绩效评估

FPNV 定位矩阵是评估出血性疾病诊断市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製出血性疾病诊断市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对出血性疾病诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争格局中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 出血性疾病盛行率增加
      • 公众和医疗保健专业人员对出血性疾病的认识和承诺正在不断增强
    • 抑制因素
      • 与先进的出血性疾病诊断方法相关的高成本
    • 机会
      • 尖端技术在出血性疾病诊断药物中的新可能性
      • 扩大照护现场出血性疾病检测设备的引进
    • 任务
      • 不同地区医疗保健监管的复杂性与动态性
  • 市场区隔分析
    • 诊断测试：用于识别与凝血因子相关的特定基因的突变和异常的基因测试变得越来越重要。
    • 适应症：出血性疾病诊断的重要用途，用于诊断各种类型的 VWD
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章出血性疾病诊断市场：透过诊断测试

  • 介绍
  • 出血时间
  • 基因检测
  • 血小板凝集试验

第七章出血性疾病诊断市场：依适应症分类

  • 介绍
  • A型血友病 A和B型血友病
  • 血小板功能障碍
  • 血管性血友病

第八章出血性疾病诊断市场：依最终用途分类

  • 介绍
  • 诊断实验室
  • 医院
  • 专科诊所

第九章北美和南美出血性疾病诊断市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区出血性疾病诊断市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章：欧洲、中东和非洲出血性疾病诊断药物市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • ARUP 实验室透过A型血友病诊断测试创造历史
    • FDA核准首个针对严重A型血友病成年患者的基因疗法
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • ARUP Laboratories
  • Baxter International Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Cepheid by Danaher Corporation
  • CSL Limited
  • F. Hoffmann-La Roche Ltd.
  • HORIBA, Ltd.
  • Hyphen BioMed by Sysmex Corporation
  • Laboratory Corporation of America Holdings
  • Novo Nordisk A/S
  • Precision BioLogic
  • rHEALTH
  • Siemens AG
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-8E373E9E2067

The Bleeding Disorder Diagnostics Market was valued at USD 662.87 million in 2023, expected to reach USD 710.26 million in 2024, and is projected to grow at a CAGR of 7.60%, to USD 1,107.09 million by 2030.

The bleeding disorder diagnostics market encompasses a range of tests and tools used to detect and diagnose bleeding disorders, such as hemophilia, Von Willebrand disease, and platelet function disorders. The necessity for precise diagnostics is driven by the need for early detection, effective management, and prevention of complications associated with these conditions. Applications primarily revolve around the use of laboratory-based coagulation tests, genetic testing, and bleeding assessments in hospitals and specialized diagnostic centers. End-users benefit from these diagnostics include healthcare providers catering to patient needs for better treatment outcomes and pharmaceutical companies focusing on drug development and clinical trials.

KEY MARKET STATISTICS
Base Year [2023] USD 662.87 million
Estimated Year [2024] USD 710.26 million
Forecast Year [2030] USD 1,107.09 million
CAGR (%) 7.60%

Key growth factors include the rise in genetic disorders, increasing awareness of bleeding disorders, and advancements in diagnostic technologies such as point-of-care testing and automation. Expanding healthcare infrastructure in emerging economies presents lucrative opportunities, as does the refinement in genomic and proteomic approaches to enhance diagnostic accuracy. Companies can tap into the market by focusing on personalized medicine and developing cost-effective, rapid diagnostic solutions. Challenges include high costs of advanced tests, limited awareness in certain regions, and strict regulatory approvals.

Innovations in molecular diagnostics and bioinformatics offer promising avenues for research and business expansion. Emphasis on R&D to develop novel biomarkers for early and precise identification of bleeding disorders is critical. Additionally, fostering collaborations with research institutions and investing in AI-driven tools for diagnostics can drive growth. The market shows a competitive nature with substantial interest from both established healthcare giants and emerging players focusing on niche areas. However, navigating regulatory landscapes and ensuring broad accessibility remain persistent challenges. Companies should prioritize affordable test solutions and strategic partnerships to enhance market penetration and sustain competitive advantage.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bleeding Disorder Diagnostics Market

The Bleeding Disorder Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of bleeding disorders
    • Growing awareness and initiatives about bleeding disorders among the general population and healthcare professionals
  • Market Restraints
    • High costs associated with advanced bleeding disorder diagnostics methods
  • Market Opportunities
    • Emerging potential of advanced technologies in bleeding disorder diagnostics
    • Growing adoption of point-of-care bleeding disorder testing devices
  • Market Challenges
    • Regulatory complexities and the dynamic nature of healthcare regulations across different regions

Porter's Five Forces: A Strategic Tool for Navigating the Bleeding Disorder Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bleeding Disorder Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bleeding Disorder Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bleeding Disorder Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bleeding Disorder Diagnostics Market

A detailed market share analysis in the Bleeding Disorder Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bleeding Disorder Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bleeding Disorder Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bleeding Disorder Diagnostics Market

A strategic analysis of the Bleeding Disorder Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bleeding Disorder Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ARUP Laboratories, Baxter International Inc., Bayer AG, Bio-Rad Laboratories, Inc., Cepheid by Danaher Corporation, CSL Limited, F. Hoffmann-La Roche Ltd., HORIBA, Ltd., Hyphen BioMed by Sysmex Corporation, Laboratory Corporation of America Holdings, Novo Nordisk A/S, Precision BioLogic, rHEALTH, Siemens AG, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Bleeding Disorder Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Diagnostic Tests, market is studied across Bleeding Time, Genetic Tests, and Platelet Aggregation Tests.
  • Based on Indication, market is studied across Hemophilia A & Hemophilia B, Platelet Function Disorders, and Von Willebrand Disease.
  • Based on End-use, market is studied across Diagnostic Laboratories, Hospitals, and Specialized Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of bleeding disorders
      • 5.1.1.2. Growing awareness and initiatives about bleeding disorders among the general population and healthcare professionals
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with advanced bleeding disorder diagnostics methods
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging potential of advanced technologies in bleeding disorder diagnostics
      • 5.1.3.2. Growing adoption of point-of-care bleeding disorder testing devices
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory complexities and the dynamic nature of healthcare regulations across different regions
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Diagnostic Tests: Growing importance of genetic testing to identify mutations or abnormalities in specific genes associated with clotting factors
    • 5.2.2. Indication: Significant applications of bleeding disorder diagnostics to diagnose different types of VWD
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bleeding Disorder Diagnostics Market, by Diagnostic Tests

  • 6.1. Introduction
  • 6.2. Bleeding Time
  • 6.3. Genetic Tests
  • 6.4. Platelet Aggregation Tests

7. Bleeding Disorder Diagnostics Market, by Indication

  • 7.1. Introduction
  • 7.2. Hemophilia A & Hemophilia B
  • 7.3. Platelet Function Disorders
  • 7.4. Von Willebrand Disease

8. Bleeding Disorder Diagnostics Market, by End-use

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories
  • 8.3. Hospitals
  • 8.4. Specialized Clinics

9. Americas Bleeding Disorder Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bleeding Disorder Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bleeding Disorder Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. ARUP Laboratories Makes History with Diagnostic Test for Hemophilia A
    • 12.3.2. FDA Approves First Gene Therapy for Adults with Severe Hemophilia A
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. ARUP Laboratories
  • 3. Baxter International Inc.
  • 4. Bayer AG
  • 5. Bio-Rad Laboratories, Inc.
  • 6. Cepheid by Danaher Corporation
  • 7. CSL Limited
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. HORIBA, Ltd.
  • 10. Hyphen BioMed by Sysmex Corporation
  • 11. Laboratory Corporation of America Holdings
  • 12. Novo Nordisk A/S
  • 13. Precision BioLogic
  • 14. rHEALTH
  • 15. Siemens AG
  • 16. Takeda Pharmaceutical Company Limited
  • 17. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. BLEEDING DISORDER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BLEEDING DISORDER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BLEEDING DISORDER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BLEEDING DISORDER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BLEEDING DISORDER DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLEEDING TIME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY PLATELET AGGREGATION TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA A & HEMOPHILIA B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY PLATELET FUNCTION DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 146. BLEEDING DISORDER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. BLEEDING DISORDER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023